ArticleBMC pediatrics2026
Nephrolithiasis associated with sulfadiazine therapy in an infant with congenital toxoplasmosis: a case report.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo describe a rare case of sulfadiazine-associated nephrolithiasis in an infant treated for congenital toxoplasmosis and to highlight the clinical implications for monitoring and management during prolonged therapy.
methodsThis study describes a single case report of an 11-month-old male infant diagnosed with congenital toxoplasmosis who developed fever, urinary tract infection, bilateral nephrolithiasis (maximum diameter approximately 1.2 cm), hydronephrosis, and renal dysfunction after 9 months of continuous treatment with sulfadiazine, pyrimethamine, and folinic acid.
resultsFollowing discontinuation of sulfadiazine and administration of intravenous antibiotics and supportive care, renal function normalized and the stones nearly resolved.
conclusionsThis case underscores the potential for severe urological adverse effects associated with sulfadiazine therapy in infants. Close monitoring of renal function and urinary ultrasound should be undertaken during prolonged sulfadiazine therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.